Clinical Trial Update: A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating continuation of durvalumab with added stereotactic radiotherapy for non-small cell lung cancer patients with metachronous ol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Institut Claudius Regaud | Conditions: NSCLC | Phase 2 | Status: COMPLETED